

PB 39 of 2018

National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 5)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated

29 May 2018

LISA LA RANCE Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health

1 Name of Instrument

- (1) This Instrument is the National Health (Pharmaceutical Benefits early supply) Amendment Instrument 2018 (No. 5).
- (2) This Instrument may also be cited as PB 39 of 2018.

2 Commencement

This Instrument commences on 1 June 2018.

3 Amendment of National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the *National Health (Pharmaceutical Benefits—early supply) Instrument 2015* (PB 120 of 2015).

Schedule 1 Amendments

[1] Schedule 1, after entry for Cabergoline in the form Tablet 2 mg

insert:

	mscri.					
Cab	ozantinib	Tablet 20 mg	20	30	2	
Cabozantinib		Tablet 20 mg	20	30	5	
Cabozantinib		Tablet 40 mg	20	30	2	
Cabozantinib		Tablet 40 mg	20	30	5	
Cabozantinib		Tablet 60 mg	20	30	2	
Cabozantinib		Tablet 60 mg	20	30	5	
[2]	Schedule 1, omit e	ntry for Daclizumab				
[3]	Schedule 1, after e insert:	ntry for Donepezil in the form Tablet containing do	onepezil hydrocl	hloride 5 mg		
Dula	aglutide	Injection 1.5 mg in 0.5 mL single dose pre-filled pen	20	4	5	
[4]	Schedule 1, after e insert:	ntry for Flutamide				
	icasone furoate with eclidinium and nterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and	20	1	5	

insert:

Golimumab Injection 100 mg in 1 mL single use pre-filled pen	20	1	5	
--	----	---	---	--